Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 1, 2010, Pages 95-104

  Shono, Yasushi ^a   Jantratid, Ekarat ^a   Kesisoglou, Filippos ^b   Reppas, Christos ^c   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Absorption modeling; Aprepitant; Biorelevant dissolution testing; In silico simulation; Micronization; Nanosizing

Indexed keywords

APREPITANT;

AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; COMPUTER PROGRAM; DEVICE; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; FEEDING; FEMALE; FOOD; HUMAN; INTESTINE FLUID; MALE; PARTICLE SIZE; PERMEABILITY; POSTPRANDIAL STATE; SIMULATION; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH JUICE;

EID: 77955656443     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.05.009     Document Type: Article

References (48)

1. Wu Y., Loper A., Landis E., Hettrick L., Novak L., Lynn K., Chen C., Thompson K., Higgins R., Batra U., Shelukar S., Kwei G., Storey D. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 2004, 285:135-146.
2. US FDA. Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, 2000.
3. Löbenberg R., Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 2000, 50:3-12.
4. Fleisher D., Li C., Zhou Y., Pao L.H., Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin. Pharmacokinet. 1999, 36:233-254.
5. Singh B.N. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 1999, 37:213-255.
6. US FDA. Guidance for Industry: Food-effect bioavailability and fed bioequivalence studies, 2002.
7. Kaeser B., Charoin J.E., Gerber M., Oxley P., Birnboeck H., Saiedabadi N., Banken L. Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects. Int. J. Clin. Pharmacol. Ther. 2005, 43:154-162.
8. Noble S., Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
9. Martindale: The Complete Drug Reference 2009, Pharmaceutical Press, London, Chicago. S.C. Sweetman (Ed.).
10. Stegemann S., Leveiller F., Franchi D., de Jong H., Linden H. When poor solubility becomes an issue: from early stage to proof of concept. Eur. J. Pharm. Sci. 2007, 31:249-261.
11. Serajuddin A.T. Salt formation to improve drug solubility. Adv. Drug. Deliv. Rev. 2007, 59:603-616.
12. Blagden N., de Matas M., Gavan P.T., York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug. Deliv. Rev. 2007, 59:617-630.
13. Kesisoglou F., Panmai S., Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug. Deliv. Rev. 2007, 59:631-644.
14. Hauss D.J. Oral lipid-based formulations. Adv. Drug. Deliv. Rev. 2007, 59:667-676.
15. Merisko-Liversidge E., Liversidge G.G., Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18:113-120.
16. Maciejewski S., Hilleman D. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia. Pharmacotherapy 2008, 28:570-575.
17. Lentz K.A. Current methods for predicting human food effect. AAPS J. 2008, 10:282-288.
18. Custodio J.M., Wu C.Y., Benet L.Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug. Deliv. Rev. 2008, 60:717-733.
19. Gu C.H., Li H., Levons J., Lentz K., Gandhi R.B., Raghavan K., Smith R.L. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm. Res. 2007, 24:1118-1130.
20. Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998, 15:11-22.
21. Jantratid E., Janssen N., Chokshi H., Tang K., Dressman J.B. Designing biorelevant dissolution tests for lipid formulations: case example - lipid suspension of RZ-50. Eur. J. Pharm. Biopharm. 2008, 69:776-785.
22. Sunesen V.H., Pedersen B.L., Kristensen H.G., Mullertz A. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur. J. Pharm. Sci. 2005, 24:305-313.
23. Dressman J.B., Thelen K., Jantratid E. Towards quantitative prediction of oral drug absorption. Clin. Pharmacokinet. 2008, 47:655-667.
24. Parrott N., Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. 2002, 17:51-61.
25. Willmann S., Lippert J., Schmitt W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin. Drug. Metab. Toxicol. 2005, 1:159-168.
26. Nicolaides E., Galia E., Efthymiopoulos C., Dressman J.B., Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 1999, 16:1876-1882.
27. Nicolaides E., Symillides M., Dressman J.B., Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 2001, 18:380-388.
28. Paulson S.K., Hribar J.D., Liu N.W., Hajdu E., Bible R.H., Piergies A., Karim A. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug. Metab. Dispos. 2000, 28:308-314.
29. Shono Y., Jantratid E., Janssen N., Kesisoglou F., Mao Y., Vertzoni M., Reppas C., Dressman J.B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm. 2009, 73:107-114.
30. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998, 15:698-705.
31. Vertzoni M., Dressman J., Butler J., Hempenstall J., Reppas C. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur. J. Pharm. Biopharm. 2005, 60:413-417.
32. Jantratid E., Janssen N., Reppas C., Dressman J.B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 2008, 25:1663-1676.
33. Klein S. The mini paddle apparatus-a useful tool in the early developmental stage? Experiences with immediate-release dosage forms. Dissol. Technol. 2006, 13(4):6-11.
34. Majumdar A.K., Howard L., Goldberg M.R., Hickey L., Constanzer M., Rothenberg P.L., Crumley T.M., Panebianco D., Bradstreet T.E., Bergman A.J., Waldman S.A., Greenberg H.E., Butler K., Knops A., De Lepeleire I., Michiels N., Petty K.J. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J. Clin. Pharmacol. 2006, 46:291-300.
35. Macheras P., Reppas C., Dressman J.B. Biopharmaceutics of Orally Administered Drugs 1995, Ellis Horwood Ltd., London.
36. Takano R., Sugano K., Higashida A., Hayashi Y., Machida M., Aso Y., Yamashita S. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 2006, 23:1144-1156.
37. Takano R., Furumoto K., Shiraki K., Takata N., Hayashi Y., Aso Y., Yamashita S. Rate-limiting steps of oral absorption for poorly water-soluble drugs in dogs; prediction from a miniscale dissolution test and a physiologically-based computer simulation. Pharm. Res. 2008, 25(10):2334-2344.
38. Sutton S.C. Role of physiological intestinal water in oral absorption. AAPS J. 2009, 11(2):277-285.
39. Fotaki N., Symillides M., Reppas C. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur. J. Pharm. Sci. 2005, 24(1):115-122.
40. Yu L.X. An integrated model for determining causes of poor oral drug absorption. Pharml. Res. 1999, 16(12):1883-1887.
41. Willmann S., Schmitt W., Keldenich J., Lippert J., Dressman J.B. A physiological model for the estimation of the fraction dose absorbed in humans. J. Med. Chem. 2004, 47(16):4022-4031.
42. Dressman J.B., Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11(Suppl. 2):S73-S80.
43. Müller R.H., Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int. J. Pharm. 1998, 160:229-237.
44. Wu W., Nancollas G.H. A new understanding of the relationship between solubility and particle size. J. Solution Chem. 1998, 27(6):521-531.
45. Godec A., Gaberscek M., Jamnik J. Comment on the article a new understanding of the relationship between solubility and particle size by W. Wu and G.H. Nancollas. J. Solution Chem. 2009, 38(1):135-146.
46. Nancollas G.H., Wu W. Response to comment on a new understanding of the relationship between solubility and particle size by A. Godec, J. Jamnik and M. Gaderscek. J. Solution Chem. 2009, 38(1):147-148.
47. Yu L.X., Amidon G.L. A compartmental absorption and transit model for estimating oral drug absorption. Int. J. Pharm. 1999, 186(2):119-125.
48. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 2006, 23:165-176.